SCHEMBL3376397

SCHEMBL3376397

Cn1cnc(S(=O)(=O)N(Cc2ccccc2)c2cccc(C(=O)N3CCN(c4ccccc4F)CC3)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
ALDH1A1 P00352 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPK1 P28482 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
LMNA P02545 6/20 0.49
APOBEC3A P31941 1/20 0.48
APOBEC3G Q9HC16 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 2/20 0.46
TP53 P04637 1/20 0.46
PARP1 P09874 1/20 0.43
HTT P42858 1/20 0.42
HPGD P15428 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3275527 0.91 LMNA (0.51) KMT2AMEN1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL303593 0.86 LMNA (0.38) KMT2AMEN1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL304469 0.83 LMNA (0.48) KMT2AMEN1ALDH1A1SMN1; SMN2NPSR1
SCHEMBL2211106 0.83 LMNA (0.48) KMT2AMEN1ALDH1A1LMNAPARP1
SCHEMBL3378334 0.82 KMT2A (0.45) KMT2AMEN1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL2212915 0.81 MEN1 (0.58) KMT2AMEN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL18487091 0.81 LMNA (0.45) KMT2AMEN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1722793 0.81 LMNA (0.47) KMT2AMEN1ALDH1A1SMN1; SMN2MAPK1
SCHEMBL17075498 0.80 LMNA (0.45) KMT2AMEN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1722406 0.80 LMNA (0.58) KMT2AMEN1SMN1; SMN2MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP claimed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US claimed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US claimed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
EP-2342177-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-02-15 EP disclosed
US-9447033-B2 Potassium channel blockers JAPAN TOBACCO INC. (JP) 2016-09-20 US disclosed
US-20150259282-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2015-09-17 US disclosed
US-9073834-B2 Potassium channel blockers XENTION LIMITED (GB) 2015-07-07 US disclosed
US-20140221337-A1 Potassium Channel Blockers XENTION LIMITED (GB) 2014-08-07 US disclosed
US-8673901-B2 Potassium channel blockers XENTION LIMITED (GB) 2014-03-18 US disclosed
US-20100087428-A1 Novel Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221337-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 KMT2A 386/4885MEN1 608/4885ALDH1A1 1360/4885
US-20100087428-A1 Novel Potassium Channel Blockers HCN4, SCN2B, KCNH2 KMT2A 1511/4885MEN1 2747/4885ALDH1A1 3795/4885
US-20150259282-A1 Potassium Channel Blockers KCNJ2, KCNH2, KCNB1 KMT2A 386/4885MEN1 608/4885ALDH1A1 1360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.